Duality Biologics focuses on developing novel-modality drugs for oncology and autoimmune diseases, with an internal pipeline of nearly 10 best-in-class and first-in-class bispecific antibodies and ADCs. The company has built a next-generation ADC platform with global intellectual property and several candidates validated in preclinical development. Several drug candidates are at the IND stage. DualityBio plans to expand its pipeline through internal R&D as well as strategic in-licensing, out-licensing, and research collaborations globally. The recently completed Series B will fund preclinical research, clinical trials, and pipeline expansion. The company was founded in January 2020 and operates with an international team across China and the United States led by founder and CEO Dr. John Zhu.

Total raised

$90M

Funding rounds

1

Latest round

Series B

Latest activity

May 2021